Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Instituto Nacional del Cáncer "Cancer Moonshot Biobank"

11 de noviembre de 2026 actualizado por: National Cancer Institute (NCI)

Protocolo de Investigación del Biobanco Moonshot del Cáncer

This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.

Descripción general del estudio

Estado

Activo, no reclutando

Intervención / Tratamiento

Descripción detallada

PRIMARY OBJECTIVE:

I. To support current and future investigations into drug resistance and sensitivity and other National Cancer Institute (NCI)-sponsored cancer research initiatives through the procurement and distribution of multiple longitudinal biospecimens and associated data from a diverse group of cancer patients who are undergoing standard of care treatment at NCI Community Oncology Research Program (NCORP) sites and other National Clinical Trials Network (NCTN) sites.

SECONDARY OBJECTIVES:

I. To provide a service of value to study participants and their medical providers through the performance of molecular profiling assays on tumor samples in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory and reporting of results to physicians and patients that they may opt to use in clinical management, including analysis of data for acquired resistance mechanisms.

II. To enable the development of patient-derived models such as cell lines and xenografts for cancer researchers through the provision of biospecimens from up to 20% of study participants to the NCI's Patient Derived Models Repository (PDMR), a national resource available to investigators.

III. To develop and implement robust approaches in patient and provider engagement to improve understanding of biobanking and its relationship to cancer research and increase representation of minority and underserved study participants in cancer research.

IV. To develop increased capabilities in United States (U.S.) community hospitals and clinics for contribution to cancer research through biobanking activities.

V. To enable secondary research generated from the project through deposition of data in public repositories such as Cancer Research Data Commons (CRDC), The Cancer Imaging Archive (TCIA) and database of Genotypes and Phenotypes (dbGaP) and other potential NCI databases, including clinical, radiology and pathology data with an emphasis on treatment response and outcome data.

VI. To provide residual biospecimens and associated data from the project to the cancer research community.

OUTLINE:

Patients undergo collection of tissue samples during baseline and at time of disease progression and collection of blood samples throughout the study, including at time of disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected if available. Additionally, patients may undergo computed tomography (CT), positron emission tomography (PET)/CT and/or magnetic resonance imaging (MRI) throughout the study, and may undergo paracentesis on study. Patient medical records are reviewed, and data is collected for at least 5 years.

Tipo de estudio

De observación

Inscripción (Estimado)

1600

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Alabama
      • Daphne, Alabama, Estados Unidos, 36526
        • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
      • Fairhope, Alabama, Estados Unidos, 36532
        • Thomas Hospital
      • Mobile, Alabama, Estados Unidos, 36607
        • Mobile Infirmary Medical Center
      • Saraland, Alabama, Estados Unidos, 36571
        • Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
    • Arizona
      • Kingman, Arizona, Estados Unidos, 86401
        • Kingman Regional Medical Center
    • Arkansas
      • Fort Smith, Arkansas, Estados Unidos, 72903
        • Mercy Hospital Fort Smith
    • California
      • Arroyo Grande, California, Estados Unidos, 93420
        • PCR Oncology
      • Bakersfield, California, Estados Unidos, 93301
        • AIS Cancer Center at San Joaquin Community Hospital
      • Loma Linda, California, Estados Unidos, 92357
        • Veterans Affairs Loma Linda Healthcare System
      • Salinas, California, Estados Unidos, 93901
        • Salinas Valley Memorial
    • Colorado
      • Brighton, Colorado, Estados Unidos, 80601
        • Intermountain Health Platte Valley Hospital
      • Denver, Colorado, Estados Unidos, 80218
        • Saint Joseph Hospital - Cancer Centers of Colorado
      • Golden, Colorado, Estados Unidos, 80401
        • Lutheran Hospital - Cancer Centers of Colorado
      • Grand Junction, Colorado, Estados Unidos, 81501
        • Saint Mary's Hospital and Regional Medical Center
      • Lafayette, Colorado, Estados Unidos, 80026
        • Good Samaritan Hospital - Cancer Centers of Colorado
    • Connecticut
      • Hartford, Connecticut, Estados Unidos, 06102
        • Hartford Hospital
    • Delaware
      • Dover, Delaware, Estados Unidos, 19901
        • Bayhealth Hospital Kent Campus
      • Milford, Delaware, Estados Unidos, 19963
        • Bayhealth Hospital Sussex Campus
    • Florida
      • Boca Raton, Florida, Estados Unidos, 33486
        • Boca Raton Regional Hospital
      • Deerfield Beach, Florida, Estados Unidos, 33064
        • Broward Health North
      • Fort Lauderdale, Florida, Estados Unidos, 33316
        • Broward Health Medical Center
      • Tampa, Florida, Estados Unidos, 33606
        • Tampa General Hospital
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30342
        • Northside Hospital
      • Savannah, Georgia, Estados Unidos, 31405
        • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
    • Illinois
      • Bloomington, Illinois, Estados Unidos, 61704
        • Illinois CancerCare-Bloomington
      • Chicago, Illinois, Estados Unidos, 60612
        • John H Stroger Jr Hospital of Cook County
      • Chicago, Illinois, Estados Unidos, 60625
        • Swedish Covenant Hospital
      • Danville, Illinois, Estados Unidos, 61832
        • Carle at The Riverfront
      • Decatur, Illinois, Estados Unidos, 62526
        • Decatur Memorial Hospital
      • Decatur, Illinois, Estados Unidos, 62526
        • Cancer Care Specialists of Illinois - Decatur
      • Evanston, Illinois, Estados Unidos, 60201
        • NorthShore University HealthSystem-Evanston Hospital
      • Galesburg, Illinois, Estados Unidos, 61401
        • Illinois CancerCare-Galesburg
      • Glenview, Illinois, Estados Unidos, 60026
        • NorthShore University HealthSystem-Glenbrook Hospital
      • Highland Park, Illinois, Estados Unidos, 60035
        • NorthShore University HealthSystem-Highland Park Hospital
      • Mattoon, Illinois, Estados Unidos, 61938
        • Carle Physician Group-Mattoon/Charleston
      • Mount Vernon, Illinois, Estados Unidos, 62864
        • SSM Health Good Samaritan
      • Pekin, Illinois, Estados Unidos, 61554
        • Illinois CancerCare-Pekin
      • Peoria, Illinois, Estados Unidos, 61615
        • Illinois CancerCare-Peoria
      • Urbana, Illinois, Estados Unidos, 61801
        • Carle Cancer Center
      • Washington, Illinois, Estados Unidos, 61571
        • Illinois CancerCare - Washington
    • Iowa
      • Ames, Iowa, Estados Unidos, 50010
        • McFarland Clinic - Ames
      • Bettendorf, Iowa, Estados Unidos, 52722
        • University of Iowa Healthcare Cancer Services Quad Cities
      • Cedar Rapids, Iowa, Estados Unidos, 52403
        • Oncology Associates at Mercy Medical Center
      • Cedar Rapids, Iowa, Estados Unidos, 52402
        • Physicians' Clinic of Iowa PC
      • Des Moines, Iowa, Estados Unidos, 50309
        • Iowa Methodist Medical Center
      • Des Moines, Iowa, Estados Unidos, 50309
        • Blank Children's Hospital
      • Des Moines, Iowa, Estados Unidos, 50309
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
      • Iowa City, Iowa, Estados Unidos, 52242
        • University of Iowa/Holden Comprehensive Cancer Center
    • Louisiana
      • Baton Rouge, Louisiana, Estados Unidos, 70808
        • Our Lady of the Lake Physician Group
      • New Orleans, Louisiana, Estados Unidos, 70118
        • Children's Hospital New Orleans
      • New Orleans, Louisiana, Estados Unidos, 70112
        • University Medical Center New Orleans
      • Shreveport, Louisiana, Estados Unidos, 71103
        • LSU Health Sciences Center at Shreveport
    • Maine
      • Augusta, Maine, Estados Unidos, 04330
        • Harold Alfond Center for Cancer Care
      • Belfast, Maine, Estados Unidos, 04915
        • MaineHealth Waldo Hospital
      • Biddeford, Maine, Estados Unidos, 04005
        • MaineHealth Maine Medical Center - Biddeford
      • Brunswick, Maine, Estados Unidos, 04011
        • MaineHealth Cancer Care and IV Therapy - Brunswick
      • Brunswick, Maine, Estados Unidos, 04011
        • Mid Coast Hospital
      • Damariscotta, Maine, Estados Unidos, 04543
        • MaineHealth LincolnHealth Hospital
      • Farmington, Maine, Estados Unidos, 04938
        • MaineHealth Franklin Hospital
      • Lewiston, Maine, Estados Unidos, 04240
        • Saint Mary's Regional Medical Center
      • Norway, Maine, Estados Unidos, 04268
        • MaineHealth Stephens Hospital
      • Portland, Maine, Estados Unidos, 04102
        • Maine Medical Partners Surgical Care
      • Portland, Maine, Estados Unidos, 04102
        • MMP Surgical Care Casco Bay
      • Portland, Maine, Estados Unidos, 04102
        • MaineHealth Maine Medical Center - Portland
      • Rockport, Maine, Estados Unidos, 04856
        • Penobscot Bay Medical Center
      • Sanford, Maine, Estados Unidos, 04073
        • MaineHealth Cancer Care and IV Therapy - Sanford
      • Scarborough, Maine, Estados Unidos, 04074
        • Maine Children's Cancer Program
      • Scarborough, Maine, Estados Unidos, 04074
        • MaineHealth Maine Medical Center- Scarborough
      • South Portland, Maine, Estados Unidos, 04106
        • MaineHealth Cancer Care and IV Therapy - South Portland
      • South Portland, Maine, Estados Unidos, 04106
        • MaineHealth Urology - South Portland
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48106
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
      • Brighton, Michigan, Estados Unidos, 48114
        • Trinity Health Medical Center - Brighton
      • Canton, Michigan, Estados Unidos, 48188
        • Trinity Health Medical Center - Canton
      • Chelsea, Michigan, Estados Unidos, 48118
        • Chelsea Hospital
      • Grand Rapids, Michigan, Estados Unidos, 49503
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
      • Iron Mountain, Michigan, Estados Unidos, 49801
        • Dickinson County Healthcare System
      • Livonia, Michigan, Estados Unidos, 48154
        • Trinity Health Saint Mary Mercy Livonia Hospital
      • Pontiac, Michigan, Estados Unidos, 48341
        • Trinity Health Saint Joseph Mercy Oakland Hospital
    • Missouri
      • Ballwin, Missouri, Estados Unidos, 63011
        • Mercy Oncology and Hematology - Clayton-Clarkson
      • Joplin, Missouri, Estados Unidos, 64804
        • Freeman Health System
      • Joplin, Missouri, Estados Unidos, 64804
        • Mercy Hospital Joplin
      • Rolla, Missouri, Estados Unidos, 65401
        • Mercy Clinic-Rolla-Cancer and Hematology
      • Rolla, Missouri, Estados Unidos, 65401
        • Phelps Health Delbert Day Cancer Institute
      • Saint Joseph, Missouri, Estados Unidos, 64506
        • Heartland Regional Medical Center
      • Springfield, Missouri, Estados Unidos, 65807
        • CoxHealth South Hospital
      • Springfield, Missouri, Estados Unidos, 65804
        • Mercy Hospital Springfield
      • St Louis, Missouri, Estados Unidos, 63131
        • Missouri Baptist Medical Center
      • St Louis, Missouri, Estados Unidos, 63109
        • Mercy Infusion Center - Chippewa
      • St Louis, Missouri, Estados Unidos, 63141
        • Mercy Hospital Saint Louis
      • St Louis, Missouri, Estados Unidos, 63128
        • Mercy Hospital South
      • Washington, Missouri, Estados Unidos, 63090
        • Mercy Hospital Washington
    • Montana
      • Billings, Montana, Estados Unidos, 59102
        • Saint Vincent Frontier Cancer Center
      • Butte, Montana, Estados Unidos, 59701
        • Saint James Community Hospital and Cancer Treatment Center
    • Nebraska
      • Grand Island, Nebraska, Estados Unidos, 68803
        • Nebraska Cancer Specialists/Oncology Hematology West PC
    • Nevada
      • Carson City, Nevada, Estados Unidos, 89703
        • Carson Tahoe Regional Medical Center
      • Las Vegas, Nevada, Estados Unidos, 89102
        • OptumCare Cancer Care at Charleston
      • Las Vegas, Nevada, Estados Unidos, 89135
        • Alliance for Childhood Diseases/Cure 4 the Kids Foundation
      • Las Vegas, Nevada, Estados Unidos, 89144
        • Comprehensive Cancer Centers of Nevada - Town Center
      • Las Vegas, Nevada, Estados Unidos, 89148
        • Comprehensive Cancer Centers of Nevada
      • Las Vegas, Nevada, Estados Unidos, 89169
        • Comprehensive Cancer Centers of Nevada - Central Valley
      • Las Vegas, Nevada, Estados Unidos, 89103
        • Hope Cancer Care of Nevada
      • Las Vegas, Nevada, Estados Unidos, 89183
        • OptumCare Cancer Care at Fort Apache
    • New Hampshire
      • Nashua, New Hampshire, Estados Unidos, 03060
        • Saint Joseph Hospital
    • New Jersey
      • Morristown, New Jersey, Estados Unidos, 07960
        • Morristown Medical Center
      • Newton, New Jersey, Estados Unidos, 07860
        • Newton Medical Center
      • Pompton, New Jersey, Estados Unidos, 07444
        • Chilton Medical Center
      • Summit, New Jersey, Estados Unidos, 07902
        • Overlook Hospital
    • New York
      • New York, New York, Estados Unidos, 10032
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
      • The Bronx, New York, Estados Unidos, 10461
        • Montefiore Medical Center-Einstein Campus
      • The Bronx, New York, Estados Unidos, 10467
        • Children's Hospital at Montefiore
      • The Bronx, New York, Estados Unidos, 10467
        • Montefiore Medical Center - Moses Campus
      • The Bronx, New York, Estados Unidos, 10461
        • Montefiore Medical Center-Weiler Hospital
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28204
        • Novant Health Presbyterian Medical Center
      • Greenville, North Carolina, Estados Unidos, 27834
        • East Carolina University
      • Greenville, North Carolina, Estados Unidos, 27834
        • ECU Health Medical Center
      • Kernersville, North Carolina, Estados Unidos, 27284
        • Novant Health Cancer Institute - Kernersville
      • Kinston, North Carolina, Estados Unidos, 28501
        • ECU Health Oncology Kinston
      • Mount Airy, North Carolina, Estados Unidos, 27030
        • Novant Health Cancer Institute - Mount Airy
      • Pinehurst, North Carolina, Estados Unidos, 28374
        • FirstHealth of the Carolinas-Moore Regional Hospital
      • Thomasville, North Carolina, Estados Unidos, 27360
        • Novant Health Cancer Institute - Thomasville
      • Washington, North Carolina, Estados Unidos, 27889
        • Marion L Shepard Cancer Center - ECU Health Beaufort Hospital
      • Winston-Salem, North Carolina, Estados Unidos, 27103
        • Novant Health Forsyth Medical Center
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73120
        • Mercy Hospital Oklahoma City
    • Rhode Island
      • Providence, Rhode Island, Estados Unidos, 02908
        • Roger Williams Medical Center
    • South Carolina
      • Columbia, South Carolina, Estados Unidos, 29203
        • Prisma Health Richland Hospital
      • Columbia, South Carolina, Estados Unidos, 29220
        • Prisma Health Baptist Hospital
      • Gaffney, South Carolina, Estados Unidos, 29341
        • Gibbs Cancer Center-Gaffney
      • Greenville, South Carolina, Estados Unidos, 29605
        • Prisma Health Greenville Memorial Hospital
      • Greer, South Carolina, Estados Unidos, 29651
        • Gibbs Cancer Center-Pelham
      • Spartanburg, South Carolina, Estados Unidos, 29303
        • Spartanburg Medical Center
      • Union, South Carolina, Estados Unidos, 29379
        • SMC Center for Hematology Oncology Union
    • Texas
      • San Antonio, Texas, Estados Unidos, 78229
        • Audie L Murphy VA Hospital
    • Virginia
      • Lynchburg, Virginia, Estados Unidos, 24501
        • Centra Alan B Pearson Regional Cancer Center
      • Richmond, Virginia, Estados Unidos, 23235
        • VCU Massey Cancer Center at Stony Point
      • Richmond, Virginia, Estados Unidos, 23298
        • VCU Massey Comprehensive Cancer Center
    • Washington
      • Renton, Washington, Estados Unidos, 98055
        • Valley Medical Center
      • Yakima, Washington, Estados Unidos, 98902
        • North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
    • West Virginia
      • Huntington, West Virginia, Estados Unidos, 25701
        • Edwards Comprehensive Cancer Center
      • Morgantown, West Virginia, Estados Unidos, 26505
        • Monongalia Hospital
    • Wisconsin
      • Eau Claire, Wisconsin, Estados Unidos, 54701
        • Marshfield Medical Center-EC Cancer Center
      • Marshfield, Wisconsin, Estados Unidos, 54449
        • Marshfield Medical Center-Marshfield
      • Milwaukee, Wisconsin, Estados Unidos, 53215
        • Aurora Saint Luke's Medical Center
      • Minocqua, Wisconsin, Estados Unidos, 54548
        • Marshfield Medical Center - Minocqua
      • Rice Lake, Wisconsin, Estados Unidos, 54868
        • Marshfield Medical Center-Rice Lake
      • Stevens Point, Wisconsin, Estados Unidos, 54482
        • Marshfield Medical Center-River Region at Stevens Point
      • Weston, Wisconsin, Estados Unidos, 54476
        • Marshfield Medical Center - Weston
      • Wisconsin Rapids, Wisconsin, Estados Unidos, 54494
        • Marshfield Clinic - Wisconsin Rapids Center
      • San Juan, Puerto Rico, 00917
        • San Juan Community Oncology Group
      • San Juan, Puerto Rico, 00927
        • Centro Comprensivo de Cancer de UPR
      • San Juan, Puerto Rico, 00936
        • San Juan City Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

13 años y mayores (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Patients undergoing treatment for cancer types with commercially available therapies.

Descripción

Inclusion Criteria:

  • Is consistent with OR has been diagnosed with one of the following:

    • Colorectal cancer: stage IV

    • Non-small cell or small cell lung cancer: stage III/IV

    • Prostate cancer: metastatic prostate cancer

    • Gastric cancer, not otherwise specified (NOS): stage IV

    • Esophageal cancer, NOS: stage IV

    • Adenocarcinoma of gastroesophageal junction: stage IV

    • High grade serous ovarian cancer: stage III/IV

    • Invasive breast carcinoma: stage III/IV

    • Melanoma: stage III/IV

    • Acute myeloid leukemia

    • Multiple myeloma

      • For the purposes of this study,

        • Re-staging is allowed
        • Having more than one primary cancer is allowed, if the patient is being treated solely for one of the eligible cancers listed above
  • Patient should fit in one of the following four clinical scenarios (a-d)

    • Undergoing diagnostic workup for one of the diseases listed for which treatment will likely include a new regimen of standard of care therapy OR
    • Scheduled to begin treatment with a new regimen of standard of care therapy OR
    • Currently progressing on a regimen of standard of care therapy OR
    • Currently being treated with a regimen standard of care therapy, without evidence of progression
  • Requirements for fresh tissue biospecimen collections at enrollment:

    • For clinical scenarios a, b, and c above, freshly collected tumor tissue or bone marrow (BM) aspirate must be submitted at enrollment

      • For clinical scenarios a and b, the fresh tissue collection must be prior to starting therapy

      • For clinical scenario a, the biospecimen collection must be part of a standard of care medical procedure

      • For clinical scenarios b or c, the biospecimen collection may be part of a standard of care medical procedure OR

      • The biospecimen collection may be part of a study-specific procedure ("research only biopsy"), when the patient has a tumor amenable to image guided or direct vision biopsy and is willing and able to undergo a tumor biopsy for molecular profiling

        • Note: For research-only biopsies, the biopsy must not be associated with a significant risk of severe or major complications or death; the procedure cannot be a mediastinal, laparoscopic, open or endoscopic biopsy; nor can the procedure be a brain biopsy; nor can the patient be under the age of majority as determined by each U.S. state
  • Requirements for archival tissue:

    • For clinical scenarios a and b above, archival tissue as outlined below must be submitted IF AVAILABLE

    • For clinical scenarios c and d above, archival tissue as outlined below is REQUIRED

    • Pre-existing archival material (formalin-fixed, paraffin-embedded [FFPE] block, BM aspirate, or unstained slides) that:

      • Contains the cancer type for which the participant is enrolled, and
      • Was collected no more than 5 years prior to initiation of therapy, and
      • Contains at least a surface area of 5 mm^2 and optimal surface area of 25 mm^2 or 3-5 mL cryopreserved bone marrow aspirate to yield 200 million bone marrow mononuclear cells, and
      • Contains at least 10% tumor content. 70% tumor content is optimal, and
      • No more than 1 line of standard of care systemic therapy was administered from the date of archival material collection to the date of initiation of therapy
  • Requirements for blood collection: ALL scenarios require fresh blood collection at enrollment

    • Blood collection for clinical scenarios a, b, and c must take place within 1 week of fresh tumor specimen collection
    • Blood collection for clinical scenario d must take place within 4 weeks of enrollment, and while patient is on treatment
  • Age 13 or older

  • Any sex

  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2

  • Ability to understand and willingness to sign an informed consent document. Consent may be provided by a Legally Authorized Representative (LAR) in accordance with 45 CFR 46.102(i)

  • NCI PDMR INCLUSION CRITERIA: Patients with CRC with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) status

  • NCI PDMR INCLUSION CRITERIA: Patients with CRC who are 40 years old or younger at time of collection irrespective of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) status

  • NCI PDMR INCLUSION CRITERIA: Patients with BRCA that are either

    • Any race/ethnicity with hormone receptor positive (ER+PR+, ER+PR-, or ER-PR+)
    • African American with triple negative (ER-PR-HER2-)
  • NCI PDMR INCLUSION CRITERIA: Patients with lung cancer (LCA), prostate cancer (PCA), gastroesophageal cancer (GEC), ovarian cancer (OV), acute myeloid leukemia (AML), multiple myeloma (MML)

Exclusion Criteria:

  • Treated with or has already begun treatment with a non-standard of care therapeutic agent (investigational) in an interventional clinical trial

    • For the purposes of this study, past enrollment in clinical trials whereby the patient was randomized and treated with standard-of-care anti-cancer treatment (chemotherapy regimen, surgery and radiation therapy) is allowed
  • Uncontrolled intercurrent illness that in the physician's assessment would pose undue risk for biopsy

  • Use of full dose coumarin-derivative anticoagulants such as warfarin are prohibited. Patients may be switched to low molecular weight (LMW) heparin at physician discretion

    • Low molecular weight (LMW) heparin is permitted for prophylactic or therapeutic use

    • Factor X inhibitors are permitted

    • Use of anti-platelet drugs are permitted

      • Stopping the anticoagulation treatment for biopsy, bone marrow aspirate, or resection should be per site standard operating procedure (SOP)
  • NCI PDMR EXCLUSION CRITERIA: Patients with complete response

  • NCI PDMR EXCLUSION CRITERIA: Patients with invasive fungal infections

  • NCI PDMR EXCLUSION CRITERIA: Patients with active and/or uncontrolled infections or who are still recovering from an infection

    • Actively febrile patients with uncertain etiology of febrile episode
    • All antibiotics for non-prophylactic treatment of infection should be completed at least 1 week (7 days) prior to collection
    • No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
  • NCI PDMR EXCLUSION CRITERIA: Patients with human immunodeficiency virus (HIV), active or chronic hepatitis (i.e. quantifiable hepatitis B virus [HBV]-deoxyribonucleic acid [DNA] and/or positive hepatitis B surface antigen [HbsAg], quantifiable hepatitis C virus [HCV]-ribonucleic acid [RNA]) or known history of HBV/HCV without documented resolution

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Observational (biospecimen collection, chart review)

Patients undergo collection of tissue samples during baseline and at time of disease progression and collection of blood samples throughout the study, including at time of disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected if available. Additionally, patients may undergo CT, PET/CT and/or MRI throughout the study, and may undergo paracentesis on study. Patient medical records are reviewed, and data is collected for at least 5 years.

Undergo CT

Otros nombres:
  • Connecticut
  • GATO
  • Análisis de gato
  • Tomografía Axial Computarizada
  • Tomografía axial computarizada
  • Tomografía computarizada
  • tomografía
  • Tomografía axial computarizada (procedimiento)
  • Tomografía computarizada (TC)
  • Escaneo de gato de diagnóstico
  • Tipo de servicio de escaneo de gato de diagnóstico

Undergo MRI

Otros nombres:
  • Resonancia magnética
  • Resonancia magnetica
  • Exploración de imágenes por resonancia magnética
  • Imágenes Médicas, Resonancia Magnética / Resonancia Magnética Nuclear
  • SRES
  • Imágenes de RM
  • Imágenes de RMN
  • RMN
  • Imágenes de resonancia magnética nuclear
  • Imágenes por resonancia magnética (IRM)
  • resonancia magnética nuclear
  • Imágenes por resonancia magnética (procedimiento)
  • Resonancias magnéticas
  • Resonancia magnética estructural

Undergo PET/CT

Otros nombres:
  • Imágenes médicas, tomografía por emisión de positrones
  • MASCOTA
  • Escaneo de mascotas
  • Tomografía por emisión de positrones
  • Tomografía de emisión de positrones
  • PT
  • Tomografía por emisión de positrones (procedimiento)

Undergo collection of blood, tissue, bone marrow, and cerebral spinal fluid samples

Otros nombres:
  • Recolección de muestras biológicas
  • Muestra biológica recolectada
  • Coleccion de especimenes
  • Recolección de muestras

Medical charts are reviewed and data is collected

Otros nombres:
  • Resumen de la tabla

Undergo paracentesis

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Procure, store and distribute longitudinal biospecimens and associated clinical data
Periodo de tiempo: Up to 10 years

Will procure, store and distribute longitudinal biospecimens and associated clinical data for current and future cancer research in order to elucidate molecular mechanisms of sensitivity and intrinsic or acquired resistance to standard of care systemic therapies, including immunotherapy. Cases will be grouped according to patient demographics, cancer type and treatment regimen. Statistical analysis will be descriptive and will be analyzed for each Biospecimen Source Site (BSS) as well as study aggregate.

Up to 10 years
Percentage of enrolled patients by cancer type and treatment regimen overall
Periodo de tiempo: Until completion of biospecimen collection, up to 3 years

Will assess the percentage of enrolled patients by cancer type and treatment regimen overall and those who contribute samples to the Drug Resistance and Sensitivity Network and other approved investigators. Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate.

Until completion of biospecimen collection, up to 3 years
Percentage of minority and underserved study participants accrued
Periodo de tiempo: Until completion of biospecimen collection, up to 3 years

Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate.

Until completion of biospecimen collection, up to 3 years

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of minority and underserved study participants accrued
Periodo de tiempo: Until completion of biospecimen collection, up to 3 years

Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate.

Until completion of biospecimen collection, up to 3 years
Pan-cancer gene panel tumor next generation sequencing test
Periodo de tiempo: Until completion of biospecimen collection, up to 3 years

Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate.

Until completion of biospecimen collection, up to 3 years
Cancer Research Data Commons, The Cancer Imaging Archive and database of Genotypes and Phenotypes data contribution
Periodo de tiempo: Until completion of biospecimen collection, up to 3 years

Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate.

Until completion of biospecimen collection, up to 3 years
Percentage of enrolled patients for whom molecular profiling is attempted
Periodo de tiempo: Until completion of biospecimen collection, up to 3 years

Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen.

Until completion of biospecimen collection, up to 3 years
Percentage of enrolled patients for whom molecular profiling results are generated
Periodo de tiempo: Until completion of biospecimen collection, up to 3 years

Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen.

Until completion of biospecimen collection, up to 3 years
Percentage of enrolled patients for whom samples are obtained at each longitudinal timepoint
Periodo de tiempo: Until completion of biospecimen collection, up to 3 years

Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen.

Until completion of biospecimen collection, up to 3 years
Percentage of collected biospecimens that are delivered to the Patient Derived Models Repository
Periodo de tiempo: Until completion of biospecimen collection, up to 3 years

Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen.

Until completion of biospecimen collection, up to 3 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Lyndsay N Harris, National Cancer Institute (NCI)

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

11 de noviembre de 2020

Finalización primaria (Estimado)

30 de abril de 2027

Finalización del estudio (Estimado)

30 de abril de 2027

Fechas de registro del estudio

Enviado por primera vez

18 de marzo de 2020

Primero enviado que cumplió con los criterios de control de calidad

18 de marzo de 2020

Publicado por primera vez (Actual)

19 de marzo de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • NCI-2020-00750
  • NCI-2020-00750 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
  • 10323 (Otro identificador: CTEP)
  • 10323 (Otro identificador: Division of Cancer Treatment and Diagnosis)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .